8-K

RETRACTABLE TECHNOLOGIES INC (RVP)

8-K 2020-06-30 For: 2020-06-30
View Original
Added on April 06, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington**,D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) ofthe Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) June 30, 2020
Retractable<br> Technologies, Inc.
---
(Exact name of registrant as specified in its charter)
Texas 001-16465 75-2599762
--- --- ---
(State or other jurisdiction<br><br> of incorporation) (Commission<br><br> File<br>Number) (IRS<br>Employer<br><br> Identification No.)
511<br> Lobo Lane, Little Elm, Texas 75068-5295
--- ---
(Address<br> of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (972) 294-1010
--- ---
None
---
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock RVP NYSE American

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On June 30, 2020, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing the declaration of a dividend to the Series I and II Class B Convertible Preferred Stock shareholders.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits

99 Press release announcing the declaration of a dividend to the Series I and II Class B Convertible Preferred Stock shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE:  June 30, 2020 RETRACTABLE TECHNOLOGIES, INC.
(Registrant)
BY: /s/ John w. Fort III
JOHN W. FORT III
VICE<br>PRESIDENT, CHIEF FINANCIAL OFFICER, AND
CHIEF ACCOUNTING OFFICER

Exhibit 99

RETRACTABLE TECHNOLOGIES, INC. DECLARESDIVIDENDS TO SERIES I AND II CLASS B CONVERTIBLE PREFERRED STOCK SHAREHOLDERS

LITTLE ELM, Texas, June 30, 2020—Retractable Technologies, Inc. (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $12,000.00 and $42,800.00, respectively. The dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from April 1, 2020 through date of conversion or June 30, 2020 whichever is applicable. The dividends will be paid on July 20, 2020 to shareholders of record as of the close of business on July 10, 2020.

Retractable manufactures and markets VanishPoint^®^ and Patient Safe^®^ safety medical products and the EasyPoint^®^ needle. The VanishPoint^®^ syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe^®^ syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint^®^ is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint^®^ needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

For more information on Retractable, visit its website at www.retractable.com.

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.

Factors that could cause or contribute to such differences include, but are not limited to, global pandemics, potential tariffs, Retractable’s ability to maintain liquidity, maintenance of patent protection, litigation, maintenance of favorable third party manufacturing and supplier arrangements and relationships, foreign trade risk, Retractable’s ability to quickly increase capacity in response to an increase in demand, Retractable’s ability to access the market, maintain or decrease production costs, continue to finance research and development as well as operations and expansion of production, the impact of larger market players, specifically Becton, Dickinson and Company, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.

Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President and Chief Financial Officer